Delivery of chemotherapeutic drugs in tumour cell-derived microparticles

Adair J. H., Parette M. P., Altinoğlu E. I., Kester M. Nanoparticulate alternatives for drug delivery. ACS Nano 4, 4967–4970 (2010). 10.1021/nn102324e

[3]

Lammers T., Hennink W. E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99, 392–397 (2008). 10.1038/sj.bjc.6604483

[4]

Shvedova A. A., Kagan V. E., Fadeel B. Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. Annu. Rev. Pharmacol. Toxicol. 50, 63–88 (2010). 10.1146/annurev.pharmtox.010909.105819

[5]

Hu Y. L., Gao J. Q. Potential neurotoxicity of nanoparticles. Int. J. Pharm. 394, 115–121 (2010). 10.1016/j.ijpharm.2010.04.026

[6]

Lewinski N., Colvin V., Drezek R. Cytotoxicity of nanoparticles. Small 4, 26–49 (2008). 10.1002/smll.200700595

[7]

Barnard A. S. Nanohazards: knowledge is our first defence. Nat. Mater. 5, 245–248 (2006). 10.1038/nmat1615

[8]

György B. et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood 117, 39–48 (2011). 10.1182/blood-2010-09-307595

[9]

Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M. Z. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20, 1487–1495 (2006). 10.1038/sj.leu.2404296

[10]

Wolf P. The nature and significance of platelet products in human plasma. Br. J. Haematol 13, 269–288 (1967). 10.1111/j.1365-2141.1967.tb08741.x

[11]

Hugel B., Martínez M. C., Kunzelmann C., Freyssinet J. M. Membrane microparticles: two sides of the coin. Physiology 20, 22–27 (2005). 10.1152/physiol.00029.2004

[12]

Mause S. F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ. Res. 107, 1047–1057 (2010). 10.1161/circresaha.110.226456

[13]

Membrane vesicles as conveyors of immune responses

Clotilde Théry, Matias Ostrowski, Elodie Segura

Nature Reviews Immunology 2009 10.1038/nri2567

[14]

Boilard E. et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327, 580–583 (2010). 10.1126/science.1181928

[15]

Distler J. H. et al. The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis 10, 731–741 (2005). 10.1007/s10495-005-2941-5

[16]

Barry O. P., Pratico D., Lawson J. A., FitzGerald G. A. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J. Clin. Invest. 99, 2118–2127 (1997). 10.1172/jci119385

[17]

Tang K. et al. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochem. Biophys. Res. Commun. 400, 432–436 (2010). 10.1016/j.bbrc.2010.08.095

[18]

Shedden K., Xie X. T., Chandaroy P., Chang Y. T., Rosania G. R. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 63, 4331–4337 (2003).

[19]

Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus

Anirudh J. Ullal, Charles F. Reich, Megan Clowse et al.

Journal of Autoimmunity 2011 10.1016/j.jaut.2011.02.001

[20]

Simons K., Gerl M. J. Revitalizing membrane rafts: new tools and insights. Nat. Rev. Mol. Cell. Biol. 11, 688–699 (2010). 10.1038/nrm2977

[21]

Riganti C. et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting p-glycoprotein in human cancer cells. Mol. Pharm. 8, 683–700 (2011). 10.1021/mp2001389

[22]

Rajendran L., Knölker H. J., Simons K. Subcellular targeting strategies for drug design and delivery. Nat. Rev. Drug. Discov. 9, 29–42 (2010). 10.1038/nrd2897

[23]

Collins A., Warrington A., Taylor K. A., Svitkina T. Structural organization of the actin cytoskeleton at sites of clathrin-mediated endocytosis. Curr. Biol. 21, 1167–1175 (2011). 10.1016/j.cub.2011.05.048

[24]

Soldati T., Schliwa M. Powering membrane traffic in endocytosis and recycling. Nat. Rev. Mol. Cell Biol. 7, 897–908 (2006). 10.1038/nrm2060

[25]

Nightingale T. D. et al. Actomyosin II contractility expels von Willebrand factor from Weibel-Palade bodies during exocytosis. J. Cell Biol. 194, 613–629 (2011). 10.1083/jcb.201011119

[26]

Masedunskas A. et al. Role for the actomyosin complex in regulated exocytosis revealed by intravital microscopy. Proc. Natl Acad. Sci. USA 108, 13552–13557 (2011). 10.1073/pnas.1016778108

[27]

Bermejo C. et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J. Urol. 177, 1335–1338 (2007). 10.1016/j.juro.2006.11.038

[28]

Atallah E. et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 110, 3547–3551 (2007). 10.1182/blood-2007-06-095844

[29]

Dvorak A. M. et al. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukoc. Biol. 59, 100–115 (1996). 10.1002/jlb.59.1.100

[30]

Davizon P., Munday A. D., López J. A. Tissue factor, lipid rafts, and microparticles. Semin. Thromb. Hemost. 36, 857–864 (2010). 10.1055/s-0030-1267039

[31]

Del Conde I., Shrimpton C. N., Thiagarajan P., López J. A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106, 1604–1611 (2005). 10.1182/blood-2004-03-1095

[32]

White E. Entosis: it’s a cell-eat-cell world. Cell 131, 840–842 (2007). 10.1016/j.cell.2007.11.015

[33]

Lugini L. et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 66, 3629–3638 (2006). 10.1158/0008-5472.can-05-3204

[34]

Greenberg S., Grinstein S. Phagocytosis and innate immunity. Curr. Opin. Immunol. 14, 136–145 (2002). 10.1016/s0952-7915(01)00309-0

[35]

Litvack M. L., Post M., Palaniyar N. IgM promotes the clearance of small particles and apoptotic microparticles by macrophages. PLoS One 6, e17223 (2011). 10.1371/journal.pone.0017223

[36]

Munari F. et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood 117, 6612–6616 (2011). 10.1182/blood-2010-06-293266

[37]

Movahedi K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728–5739 (2010). 10.1158/0008-5472.can-09-4672

[38]

Pollard J. W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 9, 259–270 (2009). 10.1038/nri2528

[39]

Hagemann T. et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205, 1261–1268 (2008). 10.1084/jem.20080108

[40]

Villa R. et al. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 14, 4134–4140 (2008). 10.1158/1078-0432.ccr-08-0099

[41]

Miselis N. R., Wu Z. J., Van Rooijen N., Kane A. B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 7, 788–799 (2008). 10.1158/1535-7163.mct-07-0579

[42]

Takei Y., Takigahira M., Mihara K., Tarumi Y., Yanagihara K. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res. 71, 1442–1453 (2011). 10.1158/0008-5472.can-10-2530

[43]

A Perspective on Cancer Cell Metastasis

Christine L. Chaffer, Robert A. Weinberg

Science 2011 10.1126/science.1203543

[44]

Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053–1064 (2010). 10.2353/ajpath.2010.100105

[45]

Tan D. S., Agarwal R., Kaye S. B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7, 925–934 (2006). 10.1016/s1470-2045(06)70939-1

[46]

Monsky W. L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59, 4129–4135 (1999).

[47]

Roberts W. G., Palade G. E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 57, 765–772 (1997).

[48]

Tan M. L., Choong P. F., Dass C. R. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J. Pharm. Pharmacol. 61, 131–142 (2009). 10.1211/jpp.61.02.0001

[49]

Ali I. et al. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 11, 135–146 (2011). 10.2174/156800911794328493

[50]

Murphy E. A. et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105, 9343–9348 (2008). 10.1073/pnas.0803728105

Showing 50 of 57 references

Cited By

414

Succinate-loaded tumor cell–derived microparticles reprogram tumor-associated macrophage metabolism

Shuya Lu, Jiexiao Li · 2025

Science Translational Medicine

Protein cargo in extracellular vesicles as the key mediator in the progression of cancer

Klára Hánělová, Martina Raudenska · 2024

Cell Communication and Signaling

Engineered tumor microvesicles modified by SP94 peptide for arsenic trioxide targeting drug delivery in liver cancer therapy

Faisal Raza, Mengyuan Zheng · 2023

Biomaterials Advances

Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study

Xiaorong Dong, Yu Huang · 2022

Frontiers in Immunology

Efficient encapsulation of biocompatible nanoparticles in exosomes for cancer theranostics

Tanziela Tanziela, Sana Shaikh · 2020

Nano Today

Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Mengfei Guo, Feng Wu · 2019

Science Translational Medicine

Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic

Hong-Hui Wu, Yi Zhou · 2019

Journal of Controlled Release

Extracellular vesicles for drug delivery

Pieter Vader, Emma A. Mol · 2016

Advanced Drug Delivery Reviews

Metrics

414

Citations

57

References

Details

Published: Dec 18, 2012
Vol/Issue: 3(1)
License: View

Authors

National Lab of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences

Department of Chemistry, Stanford University, Stanford, CA 94305; and

Cite This Article

Ke Tang, Huafeng Zhang, Pingwei Xu, et al. (2012). Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nature Communications, 3(1). https://doi.org/10.1038/ncomms2282

Delivery of chemotherapeutic drugs in tumour cell-derived microparticles

You May Also Like